Cloudflare Option Alert: Jan, 2027 $175 Calls Sweep (7) near the Ask: 501 vs 514 OI

Cloudflare Option Alert: Jan, 2027 $175 Calls Sweep (7) near the Ask: 501 @ $47.786 vs 514 OI; Ref=$165.83

Cloudflare Option Alert: Mar 21 $165 Puts at the Bid: 1000 vs 303 OI

Cloudflare Option Alert: Mar 21 $165 Puts at the Bid: 1000 @ $5.81 vs 303 OI; Ref=$173.535

Cloudflare (NYSE:NET) 주식

Cloudflare

Cloudflare is a software company based in San Francisco, California, that offers security and web performance offerings by utilizing a distributed, serverless content delivery network, or CDN. The firm's edge computing platform, Workers, leverages this network by providing clients the ability to deploy, and execute code without maintaining servers.

Comments From Palantir’s CTO

Equities

Large Cap

News

Movers

Trading Ideas

AFRM

DOCS

EXPE

MPWR

PINS

PLTR

SMCI

SPOT

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 팔란티어 테크놀로지스(NASDAQ:PLTR)의 주식은 회사가 강력한 4분기 재무 결과를 발표한 후 34.38% 급등했다. 여러 애널리스트들도 목표 주가를 상향 조정했다.

팔란티어, 슈퍼 마이크로 컴퓨터 및 스포티파이 등 지난주 상승한 10개 대형주 (2월 3일-2월 7일)

Cathie Wood Dumps Tesla Stock Ahead Of Q4 Earnings, Ark Invest Loads Up On Amazon

Short Sellers

Markets

Tech

ETFs

ACCD

AMZN

ARKF

ARKG

ARKK

ARKQ

ARKW

ARKX

HOOD

PATH

RBLX

RKLB

TWST

금요일에 캐시 우드의 아크 인베스트가 아마존닷컴(NASDAQ:AMZN), 로빈후드 마켓(NASDAQ:HOOD), 팔란티어 테크놀로지스(NYSE:PLTR) 그리고 로블록스(NYSE:RBLX) 등 여러 주요 기업의 주식에 대해 중요한 거래를 진행했다.

아크 인베스트는 팔란티어 지분을 줄이고 아마존, 로블록스 및 일루미나에 대한 큰 베팅

Stuttgart,,Germany,-,06-17-2023:,Person,Holding,Cellphone,With,Web,Page

Earnings

After-Hours Center

클라우드플레어(NYSE:NET)는 목요일(6일) 장 마감 이후 4분기 재무 실적을 발표했다. 주요 수치는 다음과 같다.

클라우드플레어, 강력한 4분기 실적 발표로 주가 11% 급등

Cloudflare Inc

NABORS ENERGY TRANSITION CORP COM

Nabors Energy Transition Corp. II - Class A Ordinary Shares

Nabors Energy Transition Corp II

Nabors Energy Transition Corp. II - Warrant

NETCOMPANY GROUP AS ADR by Netcompany Group AS

Netcompany Group AS

ENETI INC SHS

NETLease Corporate Real Estate ETF

NetLink NBN Trust

NETOBJECTS INC by NetObjects, Inc.

NetEase Inc

Network Media Group Inc

NETWORK MEDIA GROUP INC by Network Media Group Inc.

WIIM

Xinyuan Real Estate shares are trading lower amid reports indicating creditors are seeking to force the company into bankruptcy protection.

Editor's note: This article has been corrected to reflect that the price movement occurred on Tuesday.
Shares of Riot Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) are trading lower Tuesday, nearing 52-week lows as crypto-linked stocks continue to face selling pressure amid broad investor caution and <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44681738/bitcoin-is-a-more-liquid-and-higher-volatility-version-of-gold-bernstein">recent company updates</a>.
What To Know: Bitcoin's recent decline and months of underwhelming performance appear to be adding to the negative sentiment surrounding crypto-related stocks including Bitcoin miner Riot.
Bitcoin has struggled to hold support levels and has trended lower since January amid rising tariff uncertainty. Tariffs don&#8217;t directly impact cryptocurrencies, but crypto-related assets have faced selling pressure due to a general risk-off sentiment.
Although the Trump administration&#8217;s recent 90-day pause on reciprocal tariffs offered slight relief for broader markets, investors remain cautious ahead of upcoming earnings and rising trade tensions with China.
Riot Platforms has not been spared from industry-specific pressures. Analyst John Todaro from Needham <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44672428/analyst-warns-tariffs-could-push-us-bitcoin-mining-build-costs-20-higher">warned earlier this month</a> that newly imposed tariffs could raise U.S. Bitcoin mining infrastructure costs by around 20%. 
Riot, among other miners, is expected to face increased capital expenditures for future site builds, reflecting higher materials and equipment costs due to dependence on Asian manufacturing, the analyst said. While these costs do not affect current operations, they put pressure on long-term growth plans and margins.
With tariff uncertainty lingering across markets, investors are shifting their attention to the upcoming earnings season. Riot is expected to report earnings at the end of the month. Analysts anticipate a loss of 12 cents per share on revenue of $158.64 million, per <a href="http://pro.benzinga.com">Benzinga Pro</a> estimates. 
Riot reports mining metrics on a monthly basis. The company said at the beginning of the month that it produced 533 Bitcoin in March, up from 470 Bitcoin produced in February. Riot attributed the increased mining production to operational improvements across onsite teams. Investors will be looking for further mining operation updates when the company reports first-quarter results.
RIOT Price Action: Riot has a 52-week high of $15.87 and a 52-week low of $6.22. Riot shares were down 6.66% at $6.54 at the time of publication Tuesday, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0415"><img loading="lazy" decoding="async" width="1024" height="536" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15144846/Screenshot-2025-04-15-at-14.48.28-1024x536.png" alt="" class="wp-image-872835" style="width:479px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15144846/Screenshot-2025-04-15-at-14.48.28-1024x536.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15144846/Screenshot-2025-04-15-at-14.48.28-300x157.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15144846/Screenshot-2025-04-15-at-14.48.28-768x402.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15144846/Screenshot-2025-04-15-at-14.48.28-1536x803.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15144846/Screenshot-2025-04-15-at-14.48.28.png 1893w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44823070/us-recession-fears-are-intensifying-but-is-bitcoin-the-real-flight-to-safety-expert-weighs-in">US Recession Fears Are &#8216;Intensifying&#8217; — But Is Bitcoin The Real Flight To Safety? Expert Weighs In</a></li>
</ul>
Image via Shutterstock.

RIOT

Riot Platforms Stock Is Nearing 52-Week Lows: What's Going On? (CORRECTED)

When markets are volatile like these days, <a href="https://www.benzinga.com/etfs">high-beta ETFs</a> and high-momentum ETFs provide huge opportunities if you have the stomach for the whipsaws.
Beta gauges a stock&#8217;s sensitivity to market action. A high-beta ETF invests in shares that tend to move more dramatically than the overall market. That is, they tend to perform better in a rally but drop harder in a decline. These funds can be highly useful for the risk-on investor during the rebound phase.
High momentum ETFs focus on stocks recently showing a strong price uptick. The rationale is based on the idea that winners tend to keep winning. These ETFs are best suited for bullish or trending market conditions.
Also Read: <a href="https://www.benzinga.com/25/04/44818473/etf-and-equity-trading-access-goes-live-on-kraken-as-platform-enters-traditional-markets">ETF, Equity Trading Access Goes Live On Kraken As Platform Enters Traditional Markets</a>
Here are some top-performing ETFs worth taking a closer look at:
<ul>
<li>Invesco S&amp;P 500 High Beta ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPHB#NYSE">SPHB</a>): Follows the 100 highest beta stocks in the S&amp;P 500, which makes it one of the most popular funds to use when markets are rebounding.</li>
</ul>
<ul>
<li>iShares MSCI USA Momentum Factor ETF (MTUM): Targets U.S. stocks with high recent returns, picking up on positive trends across industries.</li>
</ul>
<ul>
<li>Invesco Dorsey Wright Momentum ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDP#NASDAQ">PDP</a>): Applies a relative strength strategy to choose the best performers—a good one for trend-followers who desire market leader exposure.</li>
</ul>
Yet, if you want to play it safe:
<ul>
<li>Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) provides broad market exposure with a long-term growth focus.</li>
</ul>
<ul>
<li>Consumer Staples Select Sector SPDR ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>) is a defensive investment, giving stability from businesses whose products are still in demand during all economic times.</li>
</ul>
<h2 class="wp-block-heading">Market Recap: Bounce Or Just A Breather?</h2>
Wall Street continued to be volatile due to <a href="https://www.benzinga.com/topic/tariffs">tariff uncertainty</a>. At last check Monday, the Dow increased 0.78%, the Nasdaq gained 0.64%, and the S&amp;P 500 added 0.79%. Yet all three indexes fluctuated between gains and losses throughout the session—a reflection of the fragile sentiment among investors. All the indexes have inched down by less than 1% by Tuesday afternoon.
President Donald Trump temporarily exempted some tech products from new tariffs and pledged <a href="https://www.benzinga.com/25/04/44798727/auto-stocks-rise-on-trumps-comments-about-supporting-us-car-companies-whats-going-on">to &#8220;help&#8221; automakers</a>, following a recent 25% tariff. This sent shares higher.
Adding to the cheer, the CBOE Volatility Index (VIX), Wall Street&#8217;s gauge of fear, fell 3% as of today, making equities a little more attractive.
Yet, the bigger picture is conflicted. Since the April 2 tariff shock, the major indexes are 4–5% below where they stood. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44812438/exclusive-argents-new-etfs-arent-chasing-ai-or-meme-stocks-heres-what-theyre-buying-instead">Exclusive: Argent&#8217;s New ETFs Are Not Chasing AI Or Meme Stocks, Here&#8217;s What They&#8217;re Buying Instead</a></li>
</ul>
Image: Shutterstock

Broad U.S. Equity ETFs

PowerShares DWA Technical Leaders Portfolio

SPHB

ETFs For The Brave: Are These High-Octane Funds Your Best Bet To Ride An Upward Market Swing?

<a href="https://news.bloomberglaw.com/bankruptcy-law/creditors-seek-to-force-chinese-builder-xinyuan-into-bankruptcy" title="https://news.bloomberglaw.com/bankruptcy-law/creditors-seek-to-force-chinese-builder-xinyuan-into-bankruptcy">https://news.bloomberglaw.com/bankruptcy-law/creditors-seek-to-force-chinese-builder-xinyuan-into-bankruptcy</a>

Bloomberg Law, Citing Court Filing: 'Creditors Seek to Force Chinese Builder Xinyuan into Bankruptcy'

SEDG

SolarEdge Technologies shares are trading lower after Jefferies maintained an Underperform rating on the stock and lowered its price target from $12 to $9.

Rumors

ASTS

Watching AST SpaceMobile; Hearing Unconfirmed Rumor Of Takeover Chatter From M&A Blog

Novavax, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) on Tuesday released preliminary results from the SHIELD-Utah&nbsp;study investigating the effects of systemic and local reactogenicity of COVID-19 <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">vaccine doses in&nbsp;Utah</a>.
SHIELD-Utah&nbsp;was a prospective, interventional study conducted at the&nbsp;University of Utah&nbsp;Health.
The study showed Novavax&#8217;s COVID-19 Vaccine, Adjuvanted (2024-2025 Formula), targeting the JN.1 strain, resulted in fewer and less severe reactogenicity symptoms when compared with the Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)-BioNTech SE&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44808832/shield-utah-study-shows-novavaxs-covid-19-vaccine-induces-lower-reactogenicity-symptoms-compared-t" rel="noreferrer noopener">mRNA 2024-2025 vaccine</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44634464/despite-headwinds-biotech-sell-off-could-offer-buying-opportunity-bofa" rel="noreferrer noopener">Despite Headwinds, Biotech Sell-Off Could Offer Buying Opportunity: Analyst</a>
This real-world study, conducted between September and&nbsp;December 2024, also showed that the impact of symptoms on daily activities, including work and family responsibilities, was lower in recipients of Novavax&#8217;s vaccine.
&#8220;The risk of side effects or reactogenicity has been shown to be a major decision factor for those opting to get vaccinated. Our findings of lower frequency and intensity of reactogenicity symptoms from the protein-based COVID-19 vaccine observed in SHIELD-Utah&nbsp;add valuable insights to the public debate weighing choice and value of COVID-19 vaccination,&#8221; said&nbsp;Sarang K. Yoon, DO, MOH, Principal Investigator,&nbsp;University of Utah&nbsp;Health.
As in previous studies, the SHIELD study found health care workers who received the Novavax vaccine reported significantly fewer reactogenicity events than Pfizer-BioNTech recipients.
On average, Novavax recipients experienced 1.7 symptoms versus 2.8 systemic symptoms in Pfizer-BioNTech recipients.
43.8% of Pfizer-BioNTech recipients experienced at least one symptom of Grade 2 or higher compared to 24.2% of Novavax recipients.
Local reactogenicity events also showed an absolute difference of 12.5% fewer in Novavax recipients versus Pfizer-BioNTech recipients.
The impact of symptoms on daily activities, including work, showed the hours of reduced activity were lower in Novavax recipients versus Pfizer-BioNTech recipients (mean=0.7 vs. 1.4h and mean=0.8 vs. 2.4h for missed work and less productivity, respectively).
Earlier this month, the regulators missed the deadline for deciding to grant full approval to <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44613147/fda-delays-full-approval-decision-on-novavaxs-covid-19-vaccine" rel="noreferrer noopener">Novavax&#8217;s COVID-19 shot</a>.
Price Action: NVAX stock is down 3.60% at $6.18 at the last check Tuesday
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/global/25/04/44820082/global-electric-vehicle-sales-jump-in-march-what-country-leads-in-sales" target="_blank" rel="noreferrer noopener">Global Electric Vehicle Sales Jump In March: What Country Leads In Sales?</a></li>
</ul>
Image: Shutterstock

Biotech

Health Care

General

BNTX

NVAX

Novavax Covid Vaccine Shows Milder Side Effects Than Pfizer-BioNTech's Shot: Study

American Airlines Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) shares were<a href="https://www.benzinga.com/movers" target="_blank" rel="noreferrer noopener"> trading higher on Tuesday.</a>
The firm is enhancing passenger connectivity through a new partnership with AT&amp;T Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>).
The airline has announced that starting January 2026, it will provide complimentary inflight Wi-Fi to members of its AAdvantage loyalty program.
As part of the initiative, more than two million American Airlines flights annually will offer high-speed internet access at no cost, positioning the carrier as the U.S. airline with the most extensive free Wi-Fi coverage.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/04/44819457/whats-going-on-with-trump-media-technology-stock-today-4" rel="noreferrer noopener">What&#8217;s Going On With Trump Media &amp; Technology Stock Today?</a>
The complimentary service will be available on aircraft equipped with high-speed satellite internet from Viasat and Intelsat, covering about 90% of American Airlines&#8217; mainline fleet.
The airline also plans to upgrade over 500 regional aircraft with advanced Wi-Fi by the end of 2025 to support the rollout.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, AAL stock has lost over 23% in the past year. Investors can gain exposure to the stock via&nbsp;U.S. Global Jets ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JETS#NYSE">JETS</a>).
Heather Garboden, American Airlines&#8217; recently appointed chief customer officer, said the move is part of a broader mission to improve every aspect of the passenger experience.
&#8220;We&#8217;ve been working diligently to outfit our aircraft with best-in-class high-speed Wi-Fi and together with AT&amp;T are proud to offer those services at no cost to our most loyal customers,&#8221; Garboden stated.
Jenifer Robertson, executive VP and general manager of Mass Markets at AT&amp;T, stressed the importance of constant connectivity. &#8220;By advancing connectivity, everything becomes more immediate and accessible anywhere they go.&#8221; 
The free Wi-Fi benefit will be exclusive to AAdvantage members, adding another layer of value to an already popular loyalty program.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, T stock has gained over 69% in the past year. Investors can gain exposure to the stock via iShares U.S. Telecommunications ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/IYZ#BATS">IYZ</a>).
Price Action: AAL shares are trading higher by 2.77% to $9.845 at last check Tuesday, while T shares are trading higher by 1.32% to $27.56.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44807995/us-stock-futures-waver-after-two-day-rally-trumps-tariff-moves-could-end-a-3-year-rolling-recession-says-expert" target="_blank" rel="noreferrer noopener">US Stock Futures Waver After Two-Day Rally: Trump&#8217;s Tariff Moves Could End A 3-Year ‘Rolling Recession,&#8217; Says Expert</a></li>
</ul>
Photo: Shutterstock

Travel

iShares Dow Jones US Telecommunications Sector Index Fund

JETS

What's Going On With American Airlines Stock Today?

Bank of America Securities analyst Steve Byrne downgraded Dow Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>) to Underperform from Buy, <a href="https://www.benzinga.com/quote/DOW/analyst-ratings" target="_blank" rel="noreferrer noopener">lowering the price forecast from $44 <a href="https://www.benzinga.com/quote/DOW/analyst-ratings" target="_blank" rel="noreferrer noopener">to $28</a>.</a>
The analyst cited a combination of weakening macroeconomic conditions, rising U.S. feedstock costs, and increasing trade barriers as factors creating a &#8220;perfect storm&#8221; for the company.
As a result, Byrne has significantly reduced EBITDA forecasts for 2025 and 2026 by 17% and 23%, respectively. He now expects $4.8 billion and $5.4 billion.
The company&#8217;s current valuation is less &#8220;attractive,&#8221; the analyst writes.
Also Read: <a href="https://www.benzinga.com/news/earnings/25/04/44817677/citigroup-ceo-jane-fraser-bets-us-will-still-be-worlds-leading-economy-and-dollar-the-reserve-currency-after-trade-uncertainty-settles" target="_blank" rel="noreferrer noopener">Citigroup CEO Bets US Will Be World&#8217;s Leading Economy And Dollar &#8216;Reserve Currency&#8217; After Trade Uncertainty Settles</a>
Adding to the pressure, Dow&#8217;s annual dividend of around $2 billion is now seen as increasingly at risk. Projected free cash flow shortfalls for 2025-26 will widen to $2.6 billion from the previously estimated $1.25 billion, Byrne says.
Net leverage is also expected to approach 3x through 2027.
Byrne expressed concerns that Dow&#8217;s reliance on sectors like housing, construction, and automotive could significantly pressure its earnings amid a slowing global economy.
While roughly 30% of Dow&#8217;s revenue stems from the more resilient packaging segment, the company&#8217;s strong dependence on polyethylene exports poses a notable risk, the analyst writes.
The U.S. is a major net exporter of polyethylene—accounting for 40%-50% of Dow&#8217;s sales—with China alone representing over 20% of these exports.
However, recent steep tariffs imposed by China threaten this critical revenue stream, Byrne adds.
The analyst has revised estimates downward due to anticipated lower volumes and weaker profit margins across Dow's key segments. Specifically for U.S. polyethylene, the analyst now expects more modest price gains—projecting increases of just 1 cent per pound over the next three months, compared to a previously expected 3 cents—followed by price declines later in the year.
This more cautious outlook stems from concerns about weakening demand and already high inventory levels.
Price Action: DOW shares are trading lower by 3.6% to $27.84 at last check Tuesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44800974/consumers-go-discount-as-tariff-pressures-mount-warns-analyst" target="_blank" rel="noreferrer noopener">Consumers Go Discount As Tariff Pressures Mount, Warns Analyst</a></li>
</ul>
Image: Shutterstock

Analyst Ratings

Dow Downgraded: Analyst Blames 'Perfect Storm' Of Weak Macro, High Costs, Trade Barriers

Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) and privately held Cyprumed GmbH signed a non-exclusive license and option agreement on Tuesday to develop oral formulations of Merck's peptides using Cyprumed's <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">drug delivery technology</a>.
Cyprumed is a drug delivery technology company based in Innsbruck, Austria. The company focuses on developing technology platforms for the oral administration of therapeutic peptides, including GLP-1 analogs, macrocycles, and mini-proteins.
Cyprumed's proprietary delivery platforms <a target="_blank" href="https://www.cyprumed.net/press-release/license-and-option-agreement-with-msd/" rel="noreferrer noopener">feature</a> tablet formulations.
Under the terms of the agreement, Merck gains non-exclusive global rights to Cyprumed's oral peptide delivery platform for an undisclosed number of targets.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44724763/pharma-industry-faces-jitters-as-trump-hints-at-historic-tariffs-bofa-outlines-probable-timeline" rel="noreferrer noopener">Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline</a>
The agreement also grants Merck the option to license Cyprumed's technology for use with individual targets exclusively.
Cyprumed will be eligible to receive up to $493 million in upfront, development, regulatory, and net sales milestones associated with the approval of any products under the collaboration.
Cyprumed may receive additional payments if Merck exercises its Exclusive License Option.
Under the agreement, the US drug giant will be responsible for the research, development, manufacturing, and commercialization of any product utilizing the Cyprumed delivery technology.
"We look forward to collaborating with the Cyprumed team to leverage their technology to help advance our macrocyclic peptide development efforts," said Allen C. Templeton, vice president of pharmaceutical sciences at MSD Research Laboratories.
Merck <a target="_blank" href="https://www.msd.com/research/product-pipeline/" rel="noreferrer noopener">has</a> two peptide therapies in development, including:
<ul>
<li>Enlicitide decanoate (MK-0616) is a Phase 3 investigational inhibitor of Proprotein convertase subtilisin/kexin type 9 (PCSK9). The company has five listed studies running for the asset under the CORALreef program. Merck is developing enlicitide decanoate in partnership with UCB Pharmaceuticals.</li>
<li>Efinopegdutide (MK-6024) is an investigational dual GLP-1/glucagon receptor agonist being developed under an agreement with Hanmi Pharmaceutical. Merck has four listed studies for the asset for Metabolic dysfunction-associated steatohepatitis.</li>
</ul>
In March, Merck&nbsp;and&nbsp;Jiangsu Hengrui Pharmaceuticals Co., Ltd entered into an exclusive license agreement for HRS-5346, an investigational oral small molecule Lipoprotein(a), or Lp(a), inhibitor currently being evaluated in a Phase 2&nbsp;<a href="https://www.benzinga.com/general/biotech/25/03/44477157/merck-partners-with-hengrui-pharma-in-177-billion-deal-for-cardiovascular-treatment" target="_blank" rel="noreferrer noopener">clinical trial in China</a>.
Lipoprotein (a), or Lp(a), is a type of lipoprotein produced in the liver that carries cholesterol, fats, and proteins in the blood.
Price Action: MRK stock is down 1.63% at $77.88 at the last check on Tuesday afternoon.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/04/44821235/texas-instruments-launches-advanced-auto-chips-to-cut-costs-and-boost-self-driving-capabilities" target="_blank" rel="noreferrer noopener">Texas Instruments Launches Advanced Auto Chips To Cut Costs And Boost Self-Driving Capabilities</a></li>
</ul>
Photo: Shutterstock

Contracts

Merck Signs Nearly $500 Million Licensing Deal With Austria-Based Cyprumed For Tablet-Based Peptide Delivery

In March this year, U.S. pharma giant Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) announced the launch of its popular weight loss drug Mounjaro (tirzepatide) in India, which is expected to have the second-largest population of overweight or <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">obese people by 2050</a>.
According to the Indian Council of Medical Research (ICMR), there are 101 million people with diabetes in India. Of these, at least 40 million are on medication.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/25/04/44756157/eli-lilly-abbvie-bristol-myers-regeneron-and-other-pharma-companies-slide-as-donald-trump-confirms-tariffs-on-pharma-companies" rel="noreferrer noopener">Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies</a>
According to a Reuters survey, the launch of Mounjaro in India has sparked a surge in patient interest, with some doctors receiving hundreds of calls about the drug. The survey included 18 doctors, patients, and weight-loss clinic operators.
&#8220;Since Mounjaro came out, we&#8217;ve seen a huge jump in customer interest,&#8221; said Suryansh Kumar, founder of Elevate Now, a weight management company, to Reuters.
Reuters cited his social media post that Elevate Now received over 200 calls in just one week about the drug.
Manipal Hospitals in Bengaluru has reported a more than 20% rise in patient inquiries about weight-loss medications, according to endocrinologist Abhijit Bhograj.
The growing interest is prompting some doctors to advise patients to learn more about these drugs before rushing to get them.
A Hyderabad-based bariatric surgeon got over 100 calls in just two days after announcing the availability of Mounjaro.
Reuters notes that Indian patients no longer need to depend on the black market for weight-loss drugs now that the treatment is available locally.
Dr. Muffazal Lakdawala, director of surgery at Sir H.N. Reliance Foundation Hospital, told Reuters that switching to Eli Lilly&#8217;s approved drug could cost patients less than half of what they were paying on the black market.
Earlier this month, two sources told Reuters that Novo Nordisk A/S&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) is trying to move up the launch of Wegovy in India to better compete with Lilly.
Lakdawala also said Eli Lilly will have an early lead over Novo Nordisk&#8217;s Wegovy. Wegovy contains semaglutide, the same ingredient as its diabetes drug Ozempic—a medication often used off-label for weight loss.
Lakdawala told Reuters that many patients using Ozempic have now switched to Mounjaro because it&#8217;s easier to get in India.
Novo may also have to price Wegovy more competitively in India. Mounjaro, a once-weekly injection approved by India&#8217;s drug regulator, is priced at 4,375 Indian rupees ($50.86) for a 5 mg vial and 3,500 rupees for a 2.5 mg vial, its lowest dose, the company told Reuters.
A patient in India may have to spend about $200 a month when taking a weekly dose of 5 mg, subject to doctor&#8217;s prescription.
Lilly has an early lead in India with Mounjaro, but that advantage may be short-lived. In 2026, the patent for semaglutide will expire in India, opening the door for competition. Major generic drugmakers like Cipla, Dr. Reddy&#8217;s, Lupin, Natco Pharma, Mankind Pharma, and Biocon are preparing to launch lower-cost versions of Ozempic. At the same time, Sun Pharmaceutical is also developing its GLP-1 treatment.
Vishal Manchanda, SVP of institutional research at Systematix Group, <a target="_blank" href="https://www.livemint.com/companies/eli-lilly-weight-loss-drug-anti-obesity-drug-mounjaro-diabetes-drug-glp-1-ozempic-cipla-dr-reddy-s-lupin-mankind-pharma-11742461296043.html" rel="noreferrer noopener">told</a> Livemint that even if 0.5% of 40 million use Mounjaro, it would fetch sales of $1.5 billion for Eli Lilly every year.
Price Action: LLY stock is up 0.22% at $755.98 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/04/44822758/sanofi-asthma-drug-misses-primary-goal-plans-for-pivotal-study" target="_blank" rel="noreferrer noopener">Sanofi Asthma Drug Misses Primary Goal, Plans For Pivotal Study</a></li>
</ul>
Photo by M7kk via Shutterstock

Asia

Media

Eli Lilly's Mounjaro Launch Triggers Weight-Loss Drug Craze In India, Novo Nordisk Seeks To Move Up Wegovy Launch

Investors with a lot of money to spend have taken a bullish stance on Altria Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MO#NYSE">MO</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MO, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 9 options trades for Altria Group.
This isn't normal.
The overall sentiment of these big-money traders is split between 55% bullish and 44%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $66,444, and 8, calls, for a total amount of $310,034.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $25.0 to $67.5 for Altria Group over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Altria Group's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Altria Group's significant trades, within a strike price range of $25.0 to $67.5, over the past month.
<h3>Altria Group Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744743673_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$14.45</td>
<td>$13.55</td>
<td>$13.6</td>
<td>$67.50</td>
<td>$66.4K</td>
<td>130</td>
<td align="right">13</td>
</tr>
<tr>
<td>MO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$6.05</td>
<td>$5.95</td>
<td>$5.95</td>
<td>$55.00</td>
<td>$61.2K</td>
<td>607</td>
<td align="right">123</td>
</tr>
<tr>
<td>MO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$32.85</td>
<td>$30.6</td>
<td>$32.85</td>
<td>$25.00</td>
<td>$55.8K</td>
<td>265</td>
<td align="right">84</td>
</tr>
<tr>
<td>MO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/18/26</td>
<td>$9.45</td>
<td>$9.4</td>
<td>$9.4</td>
<td>$50.00</td>
<td>$46.0K</td>
<td>427</td>
<td align="right">100</td>
</tr>
<tr>
<td>MO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$4.2</td>
<td>$4.0</td>
<td>$4.15</td>
<td>$57.50</td>
<td>$35.2K</td>
<td>2.2K</td>
<td align="right">85</td>
</tr>
</tbody>
</table>

<h3>About Altria Group</h3>
Altria comprises Philip Morris USA, US Smokeless Tobacco, John Middleton, Horizon Innovations, and Helix Innovations. Through its tobacco subsidiaries, Altria maintains the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the US with 42% annual share in 2024. Beyond its core business, it holds an 8% interest in the world's largest brewer, Anheuser-Busch InBev and a 41% stake in cannabis manufacturer Cronos. It also acquired vaping company Njoy Holdings in 2023 and operates a joint venture with Japan Tobacco in the heated tobacco category.
Having examined the options trading patterns of Altria Group, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Altria Group's Current Market Status</h3>
<ul>
<li>With a trading volume of 3,442,149, the price of MO is up by 0.83%, reaching $57.6.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 14 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Altria Group</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $46.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Sell rating for Altria Group, targeting a price of $46. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Altria Group with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Options

Altria Group Options Trading: A Deep Dive into Market Sentiment

Deep-pocketed investors have adopted a bearish approach towards ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in COP usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options activities for ConocoPhillips. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 36% leaning bullish and 54% bearish. Among these notable options, 6 are puts, totaling $959,100, and 5 are calls, amounting to $252,000.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $50.0 to $95.0 for ConocoPhillips over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for ConocoPhillips's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of ConocoPhillips's whale trades within a strike price range from $50.0 to $95.0 in the last 30 days. 
<h3>ConocoPhillips Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744743667_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>COP</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$5.5</td>
<td>$5.25</td>
<td>$5.33</td>
<td>$85.00</td>
<td>$746.2K</td>
<td>2.8K</td>
<td>1.5K</td>
</tr>
<tr>
<td>COP</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$2.54</td>
<td>$2.4</td>
<td>$2.46</td>
<td>$95.00</td>
<td>$123.0K</td>
<td>4.6K</td>
<td>601</td>
</tr>
<tr>
<td>COP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/21/25</td>
<td>$2.35</td>
<td>$2.34</td>
<td>$2.34</td>
<td>$60.00</td>
<td>$97.6K</td>
<td>3</td>
<td>429</td>
</tr>
<tr>
<td>COP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/25/25</td>
<td>$7.6</td>
<td>$7.4</td>
<td>$7.4</td>
<td>$79.00</td>
<td>$45.1K</td>
<td>0</td>
<td>61</td>
</tr>
<tr>
<td>COP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/21/25</td>
<td>$2.35</td>
<td>$1.77</td>
<td>$2.34</td>
<td>$60.00</td>
<td>$33.7K</td>
<td>3</td>
<td>767</td>
</tr>
</tbody>
</table>

<h3>About ConocoPhillips</h3>
ConocoPhillips is a US-based independent exploration and production firm. In 2023, it produced 1.2 million barrels per day of oil and natural gas liquids and 3.1 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2023 were 6.8 billion barrels of oil equivalent.
<h3>Present Market Standing of ConocoPhillips</h3>
<ul>
<li>Trading volume stands at 2,953,087, with COP's price down by -0.07%, positioned at $86.39.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 23 days.</li>
</ul>
<h3>What The Experts Say On ConocoPhillips</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $113.6.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from UBS persists with their Buy rating on ConocoPhillips, maintaining a target price of $111. 
&#x2A; Maintaining their stance, an analyst from RBC Capital continues to hold a Outperform rating for ConocoPhillips, targeting a price of $120. 
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Overweight rating on ConocoPhillips with a target price of $126. 
&#x2A; Maintaining their stance, an analyst from Scotiabank continues to hold a Sector Perform rating for ConocoPhillips, targeting a price of $95. 
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Overweight rating on ConocoPhillips with a target price of $116. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for ConocoPhillips, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Decoding ConocoPhillips's Options Activity: What's the Big Picture?

Throughout the last three months, 8 analysts have evaluated NOV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOV#NYSE">NOV</a>), offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $18.62, a high estimate of $23.00, and a low estimate of $13.00. A 2.0% drop is evident in the current average compared to the previous average price target of $19.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1744743665_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The perception of NOV by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Stephen Gengaro &#x7C;Stifel &#x7C;Lowers &#x7C;Buy &#x7C; $23.00&#x7C;$25.00 &#x7C; 
&#x7C;Charles Minervino &#x7C;Susquehanna &#x7C;Lowers &#x7C;Positive &#x7C; $19.00&#x7C;$21.00 &#x7C; 
&#x7C;Neil Mehta &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Sell &#x7C; $13.00&#x7C;$16.00 &#x7C; 
&#x7C;Keith Mackey &#x7C;RBC Capital &#x7C;Maintains &#x7C;Outperform &#x7C; $22.00&#x7C;$22.00 &#x7C; 
&#x7C;David Anderson &#x7C;Barclays &#x7C;Raises &#x7C;Underweight &#x7C; $13.00&#x7C;$12.00 &#x7C; 
&#x7C;Luke Lemoine &#x7C;Piper Sandler &#x7C;Raises &#x7C;Neutral &#x7C; $18.00&#x7C;$17.00 &#x7C; 
&#x7C;James Rollyson &#x7C;Raymond James &#x7C;Raises &#x7C;Outperform &#x7C; $19.00&#x7C;$18.00 &#x7C; 
&#x7C;Keith Mackey &#x7C;RBC Capital &#x7C;Raises &#x7C;Sector Perform &#x7C; $22.00&#x7C;$21.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to NOV. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of NOV compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for NOV's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into NOV's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NOV/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on NOV analyst ratings.</a>
<h2>Delving into NOV's Background</h2>
NOV (formerly National Oilwell Varco) is a leading supplier of oil and gas drilling rig equipment and products, such as downhole tools, drill pipe, and well casing. The company operates on a global scale, with international markets contributing nearly two thirds of its annual revenue.
<h3>Unraveling the Financial Story of NOV</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Challenges: NOV's revenue growth over 3M faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -1.49%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Energy sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 6.93%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): NOV's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 2.49%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): NOV's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 1.4%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: NOV's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.37.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: NOV In The Eyes Of 8 Experts

Investors with a lot of money to spend have taken a bullish stance on Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with BX, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 10 uncommon options trades for Blackstone.
This isn't normal.
The overall sentiment of these big-money traders is split between 50% bullish and 40%, bearish.
Out of all of the special options we uncovered, 4 are puts, for a total amount of $675,490, and 6 are calls, for a total amount of $325,584.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $120.0 and $155.0 for Blackstone, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Blackstone options trades today is 891.0 with a total volume of 1,560.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Blackstone's big money trades within a strike price range of $120.0 to $155.0 over the last 30 days.
<h3>Blackstone Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744743662_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$15.45</td>
<td>$11.7</td>
<td>$13.1</td>
<td>$135.00</td>
<td>$294.7K</td>
<td>0</td>
<td align="right">225</td>
</tr>
<tr>
<td>BX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$11.4</td>
<td>$10.65</td>
<td>$10.7</td>
<td>$135.00</td>
<td>$240.7K</td>
<td>1.6K</td>
<td align="right">235</td>
</tr>
<tr>
<td>BX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$15.2</td>
<td>$14.0</td>
<td>$14.0</td>
<td>$120.00</td>
<td>$140.0K</td>
<td>202</td>
<td align="right">100</td>
</tr>
<tr>
<td>BX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$9.9</td>
<td>$9.6</td>
<td>$9.9</td>
<td>$130.00</td>
<td>$99.9K</td>
<td>741</td>
<td align="right">108</td>
</tr>
<tr>
<td>BX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$6.6</td>
<td>$6.6</td>
<td>$6.6</td>
<td>$128.00</td>
<td>$51.4K</td>
<td>280</td>
<td align="right">81</td>
</tr>
</tbody>
</table>

<h3>About Blackstone</h3>
Blackstone is the world's largest alternative-asset manager with $1.108 trillion in total asset under management, including $820.5 billion in fee-earning assets under management, at the end of September 2024. The company has four core business segments: private equity (25% of fee-earning AUM and 30% of base management fees), real estate (35% and 39%), credit and insurance (31% and 24%), and multi-asset investing (9% and 7%). While the firm primarily serves institutional investors (87% of AUM), it also caters to clients in the high-net-worth channel (13%). Blackstone operates through 25 offices in the Americas (8), Europe and the Middle East (9), and the Asia-Pacific region (8).
In light of the recent options history for Blackstone, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Blackstone Standing Right Now?</h3>
<ul>
<li>With a trading volume of 3,782,894, the price of BX is up by 2.25%, reaching $133.41.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 2 days from now.</li>
</ul>
<h3>Expert Opinions on Blackstone</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $147.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Piper Sandler persists with their Neutral rating on Blackstone, maintaining a target price of $140. 
&#x2A; An analyst from Morgan Stanley has decided to maintain their Overweight rating on Blackstone, which currently sits at a price target of $150. 
&#x2A; Maintaining their stance, an analyst from Wells Fargo continues to hold a Equal-Weight rating for Blackstone, targeting a price of $139. 
&#x2A; In a positive move, an analyst from UBS has upgraded their rating to Buy and adjusted the price target to $180. 
&#x2A; An analyst from Barclays has decided to maintain their Equal-Weight rating on Blackstone, which currently sits at a price target of $129. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Blackstone, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

This Is What Whales Are Betting On Blackstone

Across the recent three months, 15 analysts have shared their insights on SolarEdge Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>), expressing a variety of opinions spanning from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">9</td>
<td align="right">4</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">3</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $16.8, a high estimate of $31.00, and a low estimate of $9.00. Marking an increase of 10.53%, the current average surpasses the previous average price target of $15.20. 
<img src="https://www.benzinga.com/files/images/story/2025/1744743658_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive SolarEdge Technologies. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;---------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Julien Dumoulin-Smith&#x7C;Jefferies &#x7C;Lowers &#x7C;Underperform &#x7C; $9.00&#x7C;$12.00 &#x7C; 
&#x7C;Biju Perincheril &#x7C;Susquehanna &#x7C;Lowers &#x7C;Neutral &#x7C; $12.00&#x7C;$17.00 &#x7C; 
&#x7C;Michael Blum &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $19.00&#x7C;$20.00 &#x7C; 
&#x7C;Philip Shen &#x7C;Roth MKM &#x7C;Raises &#x7C;Neutral &#x7C; $20.00&#x7C;$17.00 &#x7C; 
&#x7C;Julien Dumoulin-Smith&#x7C;Jefferies &#x7C;Raises &#x7C;Underperform &#x7C; $12.00&#x7C;$9.00 &#x7C; 
&#x7C;Biju Perincheril &#x7C;Susquehanna &#x7C;Raises &#x7C;Neutral &#x7C; $17.00&#x7C;$13.00 &#x7C; 
&#x7C;Brian Lee &#x7C;Goldman Sachs &#x7C;Raises &#x7C;Buy &#x7C; $31.00&#x7C;$21.00 &#x7C; 
&#x7C;Christopher Dendrinos&#x7C;RBC Capital &#x7C;Raises &#x7C;Sector Perform &#x7C; $15.00&#x7C;$14.00 &#x7C; 
&#x7C;Austin Moeller &#x7C;Canaccord Genuity &#x7C;Raises &#x7C;Hold &#x7C; $19.00&#x7C;$18.00 &#x7C; 
&#x7C;Jon Windham &#x7C;UBS &#x7C;Raises &#x7C;Neutral &#x7C; $22.00&#x7C;$18.00 &#x7C; 
&#x7C;Kashy Harrison &#x7C;Piper Sandler &#x7C;Raises &#x7C;Underweight &#x7C; $10.00&#x7C;$9.00 &#x7C; 
&#x7C;Andrew Percoco &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Equal-Weight &#x7C; $18.00&#x7C;$11.00 &#x7C; 
&#x7C;Ameet Thakkar &#x7C;BMO Capital &#x7C;Raises &#x7C;Underperform &#x7C; $15.00&#x7C;$13.00 &#x7C; 
&#x7C;Mark Strouse &#x7C;JP Morgan &#x7C;Lowers &#x7C;Overweight &#x7C; $19.00&#x7C;$21.00 &#x7C; 
&#x7C;Jordan Levy &#x7C;Truist Securities &#x7C;Lowers &#x7C;Hold &#x7C; $14.00&#x7C;$15.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to SolarEdge Technologies. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of SolarEdge Technologies compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of SolarEdge Technologies's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of SolarEdge Technologies's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/SEDG/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on SolarEdge Technologies analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering SolarEdge Technologies: A Closer Look</h2>
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers.
<h3>Financial Insights: SolarEdge Technologies</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Decline in Revenue: Over the 3M period, SolarEdge Technologies faced challenges, resulting in a decline of approximately -45.97% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: SolarEdge Technologies's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -183.26% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): SolarEdge Technologies's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -38.76%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): SolarEdge Technologies's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -11.49%, the company may face hurdles in achieving optimal financial returns.
Debt Management: SolarEdge Technologies's debt-to-equity ratio stands notably higher than the industry average, reaching 1.15. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About SolarEdge Technologies Stock

UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) is demanding swift repayment of $8.9 billion in emergency loans it issued to medical providers following a massive cyberattack on its subsidiary, <a href="https://www.benzinga.com/news/large-cap/24/02/37284799/whats-going-on-with-uanitedhealth-stock-friday" target="_blank" rel="noreferrer noopener">Change Healthcare, last year</a>.
The shutdown of Change Healthcare's systems triggered a healthcare crisis, halting medical claims&nbsp;<a target="_blank" href="https://www.benzinga.com/news/large-cap/24/04/38388554/patient-data-compromised-unitedhealth-group-admits-ransom-payment-in-cyberattack" rel="noreferrer noopener">processing for millions of transactions</a>.
The cyberattack compromised the personal data of <a target="_blank" href="https://www.benzinga.com/25/01/43215481/unitedhealth-cyberattack-exposed-personal-data-of-190-million-americans" rel="noreferrer noopener">190 million Americans</a>.
The cyberattack on&nbsp;Change Healthcare temporarily shut down services that process about 50% of all&nbsp;<a href="https://www.benzinga.com/news/large-cap/24/04/38110751/unitedhealths-change-healthcare-seeks-consolidation-of-cyberattack-lawsuits-in-nashville-court" target="_blank" rel="noreferrer noopener">U.S. medical claims</a>.
The hack affected around 900,000 doctors, 33,000 pharmacies, 5,500 hospitals and 600 labs. Although the claims system and other services are gradually being restored, the aftermath <a href="https://www.benzinga.com/news/large-cap/24/06/39190002/post-unitedhealth-cyberattack-community-health-centers-face-prolonged-disruption" target="_blank" rel="noreferrer noopener">burdened healthcare providers</a>.
The Wall Street Journal on Friday wrote that providers could not process claims, leading to cash flow issues which made it challenging to cover payroll and operating expenses.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43879859/doj-investigates-unitedhealth-probe-accuses-of-inflating-medicare-diagnoses" rel="noreferrer noopener">DOJ Investigates UnitedHealth, Probe Accuses Of Inflating Medicare Diagnoses</a>
In response, UnitedHealth, through its Optum unit, offered interest-free loans via a Temporary Funding Assistance Program, disbursing around $8.9 billion to support providers.
Despite earlier assurances that repayments would be flexible, some healthcare providers now say the company is aggressively pursuing repayments, even as they continue to struggle financially from the fallout.
&#8220;Our priority in establishing this program in March 2024 has been to help bridge the gap in short-term cash flow needs for those providers impacted by the disruption of Change Healthcare's services,&#8221; said Change Healthcare in response to Benzinga. &#8220;Now, more than one year post the event and with services restored, we have begun the process of recouping the interest-free funding we provided to providers — as HHS itself did when it began recouping payments it provided under its own cyberattack lending program in July 2024. We continue to work with providers on repayment and other options, and continue to reach out to those providers that have not been responsive to previous calls or email requests for more information.&#8221;
The WSJ report <a href="https://www.wsj.com/articles/unitedhealth-group-sends-demands-for-hack-loan-repayments-9a26376c" target="_blank" rel="noreferrer noopener">says</a> that UnitedHealth CEO Andrew Witty testified before the Senate Finance Committee in May 2024 that repayments would begin after providers confirmed their finances had stabilized and claims <a href="https://www.benzinga.com/government/24/05/38563578/us-senate-grills-unitedhealth-ceo-over-cyberattack-fallout-ransom-payment" target="_blank" rel="noreferrer noopener">backlogs were resolved</a>.
They would then have 45 business days to start repayments. As of October, the company had recovered approximately $3.2 billion of the loaned funds.
However, several providers report being blindsided by sudden repayment demands.
A Change Healthcare spokesperson defended the company's actions, comparing its loan recovery efforts to those by federal agencies following the hack. The spokesperson said Optum continues to reach out to providers and is working on repayment options for those who haven&#8217;t responded.
In December 2024, the Nebraska Attorney General&nbsp;filed&nbsp;a lawsuit against UnitedHealth and its subsidiaries, alleging violations of consumer protection laws following the breach, <a target="_blank" href="https://www.benzinga.com/general/health-care/24/12/42621731/nebraska-attorney-general-sues-unitedhealth-over-massive-data-breach-that-disrupted-healthcare" rel="noreferrer noopener">which affected 575,000 Nebraskans</a>.
The&nbsp;<a href="https://ago.nebraska.gov/sites/default/files/doc/Court%20Filing_10.pdf?tblci=GiCUX7wvU_AgmIIiQduNYr6JQuJQLy6SZJGvpyeZuCzyqiCN1VcoxvTN4f7-y-PqATDviEo" target="_blank" rel="noreferrer noopener">lawsuit</a>&nbsp;alleges that outdated systems, inadequate segmentation and the lack of redundancies at Change Healthcare exacerbated the crisis.
UnitedHealthcare has faced lawsuits over its practices, including allegations that an AI tool used by the company resulted in a high error rate and denied necessary <a target="_blank" href="https://www.benzinga.com/general/health-care/25/01/42771908/viral-tear-it-all-down-post-sparks-debate-over-unitedhealthcare-practices-alleges-denial-of-icu-care-for-comatose-patient" rel="noreferrer noopener">care to many patients</a>.
The insurance giant has garnered immense attention following the murder of its insurance unit CEO Brian Thompson in New York.
Luigi Mangione, the alleged perpetrator, pleaded not guilty to murder and weapons charges. Police found shell casings at the scene with the words "deny," "defend," and "depose," commonly associated with insurance industry strategies for&nbsp;<a target="_blank" href="https://www.benzinga.com/24/12/42710544/can-you-bet-on-luigi-mangiones-fate-betting-platforms-regulators-wrestle-with-limits" rel="noreferrer noopener">handling claims and disputes</a>.
UNH Price Action: UnitedHealth Group stock is down 0.27% at $585.13 at publication Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/04/44812561/johnson-johnson-q1-earnings-strong-cancer-drug-sales-boosts-quarterly-dividend-anticipates-negative-currency-impact-for-2025-profit" target="_blank" rel="noreferrer noopener">Johnson &amp; Johnson Q1 Earnings: Strong Cancer Drug Sales, Boosts Quarterly Dividend, Anticipates Negative Currency Impact For 2025 Profit</a></li>
</ul>
Photo: UnitedHealth Group via Shutterstock
The article was updated with a response from Change Healthcare.

Insurance

UnitedHealth Demands Rapid Repayment Of Cyberattack Relief Loan Billions, Providers Say Push Undermines Recovery (Updated)

Across the recent three months, 6 analysts have shared their insights on Science Applications Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIC#NASDAQ">SAIC</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $133.33, along with a high estimate of $148.00 and a low estimate of $115.00. A 4.99% drop is evident in the current average compared to the previous average price target of $140.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1744743649_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A clear picture of Science Applications Intl's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Seth Seifman &#x7C;JP Morgan &#x7C;Lowers &#x7C;Overweight &#x7C; $140.00&#x7C;$148.00 &#x7C; 
&#x7C;Matthew Akers &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $132.00&#x7C;$148.00 &#x7C; 
&#x7C;Tobey Sommer &#x7C;Truist Securities &#x7C;Lowers &#x7C;Hold &#x7C; $115.00&#x7C;$135.00 &#x7C; 
&#x7C;Gavin Parsons &#x7C;UBS &#x7C;Raises &#x7C;Neutral &#x7C; $126.00&#x7C;$123.00 &#x7C; 
&#x7C;Matthew Akers &#x7C;Wells Fargo &#x7C;Raises &#x7C;Overweight &#x7C; $148.00&#x7C;$139.00 &#x7C; 
&#x7C;Matthew Akers &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $139.00&#x7C;$149.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Science Applications Intl. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Science Applications Intl compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Science Applications Intl's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Science Applications Intl's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SAIC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Science Applications Intl analyst ratings.</a>
<h2>Discovering Science Applications Intl: A Closer Look</h2>
Science Applications International Corp provides technical, engineering, and enterprise IT services mainly to the U.S. government. Specifically, it offers end-to-end solutions spanning the design, development, integration, deployment, management and operations, sustainment, and security of the customer's entire IT infrastructure. The company has two reportable segments which include Defense and Intelligence and the Civilian segment. Maximum revenue is generated from its Defense and Intelligence segment, which provides a diverse portfolio of national security solutions to the Department of Defence (DoD) and the Intelligence Community of the United States Government. The Civilian segment provides solutions to the civilian markets, encompassing federal, state, and local governments.
<h3>Science Applications Intl: Delving into Financials</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Science Applications Intl showcased positive performance, achieving a revenue growth rate of 5.81% as of 31 January, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.
Net Margin: Science Applications Intl's net margin is impressive, surpassing industry averages. With a net margin of 5.33%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Science Applications Intl's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 6.15%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.86%, the company showcases effective utilization of assets.
Debt Management: Science Applications Intl's debt-to-equity ratio is below the industry average at 1.52, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SAIC

Where Science Applications Intl Stands With Analysts

Adtalem Glb Education (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATGE#NYSE">ATGE</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $117.5, a high estimate of $120.00, and a low estimate of $115.00. Surpassing the previous average price target of $109.50, the current average has increased by 7.31%.
<img src="https://www.benzinga.com/files/images/story/2025/1744743639_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive Adtalem Glb Education is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Alexander Paris &#x7C;Barrington Research &#x7C;Maintains &#x7C;Outperform &#x7C; $120.00&#x7C;$120.00 &#x7C; 
&#x7C;Jeffrey Silber &#x7C;BMO Capital &#x7C;Raises &#x7C;Outperform &#x7C; $115.00&#x7C;$108.00 &#x7C; 
&#x7C;Alexander Paris &#x7C;Barrington Research &#x7C;Raises &#x7C;Outperform &#x7C; $120.00&#x7C;$115.00 &#x7C; 
&#x7C;Alexander Paris &#x7C;Barrington Research &#x7C;Raises &#x7C;Outperform &#x7C; $115.00&#x7C;$95.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Adtalem Glb Education. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Adtalem Glb Education compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Adtalem Glb Education's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Adtalem Glb Education's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ATGE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Adtalem Glb Education analyst ratings.</a>
<h2>Get to Know Adtalem Glb Education Better</h2>
Adtalem Global Education Inc is an American for-profit educational company that operates various university and educational programs. The company has three segments namely Chamberlain; Walden; and Medical and Veterinary. It derives maximum revenue from Chamberlain segment.
<h3>Key Indicators: Adtalem Glb Education's Financial Health</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Adtalem Glb Education displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 13.86%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Adtalem Glb Education's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 16.94% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Adtalem Glb Education's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.36% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Adtalem Glb Education's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.74%, the company showcases efficient use of assets and strong financial health.
Debt Management: Adtalem Glb Education's debt-to-equity ratio stands notably higher than the industry average, reaching 0.6. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Adtalem Global Education Inc. Common Stock

ATGE

What 4 Analyst Ratings Have To Say About Adtalem Glb Education

Scilex Holding's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCLX#NYSE">SCLX</a>) short percent of float has fallen 4.27% since its last report. The company recently reported that it has 5.79 million shares sold short, which is 4.71% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.94 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Scilex Holding Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744743631_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Scilex Holding has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Scilex Holding's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Scilex Holding's peer group average for short interest as a percentage of float is 3.00%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Comments

Cloudflare

Unusual Options Activity for

뉴스

파트너 / 기고자

벤징가 글로벌

Date	Put/Call	Strike Price	Exp Date	DTE	Trade Vol	Day Vol	Vol / OI	OI	Trade Type	Sentiment
09:31 AMFeb 18, 2025	CALL	$175.00	Jan 15, 2027	639	0	501	0	514	SWEEP	BULLISH
10:27 AMFeb 13, 2025	PUT	$165.00	Mar 21, 2025	-26	1004	1000	331	303	TRADE	BULLISH